HG 248
Alternative Names: HG-248Latest Information Update: 08 Sep 2023
At a glance
- Originator HitGen
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Aug 2023 Preclinical trials in Cancer in China (unspecified route) prior to August 2023 (HitGen pipeline, August 2023)